14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
URGN vs XOMA: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, XOMA Royalty Corporation (XOMA) is the stronger overall head-to-head candidate over UroGen Pharma Ltd. (URGN) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). URGN carries a Unified Composite Score of 61.5/100 (BUY) at $28.41 (10.2x Forward P/E, -12.4% operating margin), whereas XOMA carries 55.8/100 (HOLD) at $40.17 (21.5x Forward P/E, -3.9% operating margin).
Composite vs. Pillar Nuance: While URGN currently prints a higher short-term Unified Composite Score (61.5/100 BUY vs. XOMA 55.8/100 HOLD), XOMA captures the overall institutional head-to-head verdict (5–5 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-3.9% vs. -12.4% operating margin) and revenue trajectory (-22.6% vs. +223.9% YoY).
Technical & Structure Timing Caution: URGN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.1); meanwhile XOMA trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 34.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on URGN vs XOMA. Trailing 12-month operating profitability (URGN -12.4% vs XOMA -3.9%) and valuation multiples (URGN 10.2x vs XOMA 21.5x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $781.8M market capitalization and -3.9% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ URGN vs XOMA Key Questions & Quantitative Answers
As of Nov 16, 2026, XOMA Royalty Corporation (XOMA) is the stronger overall head-to-head candidate over UroGen Pharma Ltd. (URGN) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). URGN carries a Unified Composite Score of 61.5/100 (BUY) at $28.41 (10.2x Forward P/E, -12.4% operating margin), whereas XOMA carries 55.8/100 (HOLD) at $40.17 (21.5x Forward P/E, -3.9% operating margin). Composite vs. Pillar Nuance: While URGN currently prints a higher short-term Unified Composite Score (61.5/100 BUY vs. XOMA 55.8/100 HOLD), XOMA captures the overall institutional head-to-head verdict (5–5 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-3.9% vs. -12.4% operating margin) and revenue trajectory (-22.6% vs. +223.9% YoY). Technical & Structure Timing Caution: URGN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.1); meanwhile XOMA trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 34.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
URGN leads the Growth & Scale pillar: URGN posts +223.9% YoY revenue growth and +0.0% YoY earnings growth on $250M TTM revenue (91.4% gross margin, -12.4% operating margin), compared with XOMA at -22.6% YoY revenue growth and +207.9% YoY earnings growth on $49M TTM revenue (99.0% gross margin, -3.9% operating margin). On trailing 12-month operating scale, URGN generates $250M in USD-normalized revenue versus $49M for XOMA. In operating R&D and SG&A reinvestment, URGN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for XOMA.
URGN screens cheaper on headline valuation multiples. URGN trades at 10.2x Forward P/E, 12.9x Trailing P/E, N/M PEG, and 5.5x EV/Revenue (-52.8% FCF margin), whereas XOMA trades at 21.5x Forward P/E, 28.2x Trailing P/E, N/M PEG, and 16.1x EV/Revenue (17.1% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against URGN (-1481.3% ROE) versus XOMA (34.2% ROE) capital efficiency.
In options market volatility and institutional positioning, URGN carries 112.8% implied volatility (10th %ile, Compressed (<25th %ile)), a 0.13x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.33β · 82% Vol realized risk). By comparison, XOMA carries 101.5% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.68β · 37% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.